Skip to main content
Full access
Letters to the Editor
Published Online: 1 January 2009

Drs. Shekhar, McKinzie, and Felder Reply

To the Editor: Dr. Pomara suggests that the clinical efficacy of xanomeline treatment for improving cognitive deficits in schizophrenia patients in our study (1) may not have been a result of sustained M 1 receptor agonist properties, as hypothesized by Dr. Lieberman et al. (2), but rather a result of chronic agonist-induced desensitization and downregulation of cortical M 1 receptors. Although M 1 receptor desensitization contributing to the clinical efficacy of xanomeline is certainly possible, which is supported by some of the evidence cited by Dr. Pomara, such a hypothesis is difficult to test directly. On the other hand, it is equally possible that direct agonist effects of xanomeline may contribute to cognitive benefits for the following reasons.
First, the postmortem studies by Crook et al. (3) measured 3H-pirenzapine binding, a ligand that is not a highly selective M 1 receptor antagonist and does not distinguish high versus low affinity states of the M 1 receptor. Second, muscarinic M 1 receptors appear to have a high receptor reserve requiring only a 15% occupancy to attain full signal transduction, suggesting that a significant decline in receptor number can possibly occur without causing functional consequences (4) . Thus, the conclusion by Crook et al. that reductions in M 1 receptor density in limbic regions were a result of hypercholinergic state has not been directly tested and remains speculative.
Interestingly, preclinical testing of another M 4 receptor agonist, BuTAC, demonstrated that it possesses antipsychotic-like properties similar to xanomeline. However, unlike xanomeline, BuTAC is an antagonist at the M 1 receptor and does not exhibit efficacy in spatial learning in rats. This may support the hypothesis that the cognitive benefits of xanomeline may well be the result of its agonist properties at the M 1 receptor. Unfortunately, utilizing direct orthosteric agonists of receptors, it is difficult to conclude whether the effects of chronic administration of the drug are a result of continued agonism or desensitization of its receptors. Recently published data using muscarinic receptor potentiators further support a role for M 1 and/or M 4 positive modulation, rather than antagonism, as the primary mechanism driving antipsychotic efficacy (5, 6) . With positive modulators, M 1 and M 4 receptors would be less sensitive to downregulation as a result of the allosteric mechanism of action. Indeed, positive allosteric modulation would be less prone to desensitization and would preserve spatial and temporal regulation of M 1 receptor activation (4) . Therefore, based on the high receptor reserve for the M 1 receptor, and most likely for M 4 receptor, and evidence based on recent M 1 and M 4 selective positive allosteric modulators, it is unlikely that orthosteric agonist-mediated desensitization is the sole explanation for muscarinic-based mechanisms of antipsychotic therapeutics.

Footnotes

The authors’ disclosures accompany the original article.
This letter (doi: 10.1176/appi.ajp.2008.08091352r1) was accepted for publication in October 2008.

References

1.
Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dubé S, Mallinckrodt C, Bymaster FP, McKinzie DL, Felder CC: Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry 2008; 165:1033–1039
2.
Lieberman JA, Javitch JA, Moore H: Cholinergic agonists as novel treatments for schizophrenia: the promise of rational drug development for psychiatry. Am J Psychiatry 2008; 165:931–936
3.
Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B: Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann’s areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. Am J Psychiatry 2001; 158:918–925
4.
May LT, Leach K, Sexton PM, Christopoulos A: Allosteric modulation of G protein-coupled receptors. Annu Rev Pharmacol Toxicol 2007; 47:1–51
5.
Chan WY, McKinzie DL, Bose S, Mitchell SN, Witkin JM, Thompson RC, Christopoulos A, Lazareno S, Birdsall NJ, Bymaster FP, Felder CC: Allosteric modulation of the muscarinic M 4 receptor as an approach to treating schizophrenia. Proc Natl Acad Sci U S A 2008; 105:10978–10983
6.
Jones CK, Brady AE, Davis AA, Xiang Z, Bubser M, Tantawy MN, Kane AS, Bridges TM, Kennedy JP, Bradley SR, Peterson TE, Ansari MS, Baldwin RM, Kessler RM, Deutch AY, Lah JJ, Levey AI, Lindsley CW, Conn PJ: Novel selective allosteric activator of the M 1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. J Neurosci 2008; 28:10422–10433

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 113

History

Published online: 1 January 2009
Published in print: January, 2009

Authors

Details

ANANTHA SHEKHAR, M.D., Ph.D.
DAVID L. McKINZIE, Ph.D.
CHRISTIAN C. FELDER, Ph.D.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share